Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. More Details
Exceptional growth potential with mediocre balance sheet.
Share Price & News
How has Halozyme Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HALO has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HALO exceeded the US Biotechs industry which returned 32% over the past year.
Return vs Market: HALO exceeded the US Market which returned 12.9% over the past year.
Price Volatility Vs. Market
How volatile is Halozyme Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHere's What We Think About Halozyme Therapeutics' (NASDAQ:HALO) CEO Pay
1 month ago | Simply Wall StThe Independent Director of Halozyme Therapeutics, Inc. (NASDAQ:HALO), James Daly, Just Sold 52% Of Their Holding
2 months ago | Simply Wall StIs Halozyme Therapeutics, Inc. (NASDAQ:HALO) Trading At A 45% Discount?
Is Halozyme Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HALO ($26.59) is trading below our estimate of fair value ($58.28)
Significantly Below Fair Value: HALO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HALO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: HALO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HALO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HALO is overvalued based on its PB Ratio (34.4x) compared to the US Biotechs industry average (3.6x).
How is Halozyme Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HALO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: HALO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HALO's is expected to become profitable in the next 3 years.
Revenue vs Market: HALO's revenue (26% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: HALO's revenue (26% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HALO's Return on Equity is forecast to be very high in 3 years time (83%).
How has Halozyme Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HALO is currently unprofitable.
Growing Profit Margin: HALO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HALO is unprofitable, but has reduced losses over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare HALO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HALO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: HALO has a negative Return on Equity (-37.6%), as it is currently unprofitable.
How is Halozyme Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HALO's short term assets ($500.4M) exceed its short term liabilities ($26.1M).
Long Term Liabilities: HALO's short term assets ($500.4M) exceed its long term liabilities ($395.3M).
Debt to Equity History and Analysis
Debt Level: HALO's debt to equity ratio (369.5%) is considered high.
Reducing Debt: HALO's debt to equity ratio has increased from 92.2% to 369.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HALO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HALO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Halozyme Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HALO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HALO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HALO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HALO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HALO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Helen Torley (57 yo)
Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the ...
CEO Compensation Analysis
Compensation vs Market: Helen's total compensation ($USD5.86M) is about average for companies of similar size in the US market ($USD5.63M).
Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.
|Senior VP & CFO||0.50yr||no data||no data|
|Senior VP & Chief Technical Officer||no data||US$437.90k||0.12% |
|VP, Chief Information & Security Officer||5.67yrs||no data||no data|
|Vice President of Investor Relations & Corporate Communications||1.83yrs||no data||no data|
|Senior VP||no data||no data||0.0084% |
|Vice President of Human Resources||0.67yr||no data||no data|
|Senior VP &||2.5yrs||US$708.80k||no data|
|Chief Medical Officer||0.58yr||no data||no data|
|Chief of Staff to the CEO||0.83yr||no data||no data|
Experienced Management: HALO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Independent Chairperson of the Board||no data||US$305.00k||0.15% |
|Independent Director||5.08yrs||US$290.00k||0.053% |
|Member of the Scientific Advisory Board||16.08yrs||no data||no data|
|Member of the Advisory Board||no data||no data||no data|
|Chairman of Scientific Advisory Board||6.67yrs||US$68.17k||no data|
|Member of Scientific Advisory Board||16.25yrs||no data||no data|
|Independent Director||4.5yrs||US$255.00k||0.023% |
|Independent Director||16.33yrs||US$275.00k||0.21% |
|Member of Scientific Advisory Board||15.17yrs||no data||no data|
|Independent Director||7.5yrs||US$270.00k||0.090% |
|Independent Director||5.67yrs||US$260.00k||0.060% |
Experienced Board: HALO's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HALO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Halozyme Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Halozyme Therapeutics, Inc.
- Ticker: HALO
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.638b
- Shares outstanding: 136.82m
- Website: https://www.halozyme.com
Number of Employees
- Halozyme Therapeutics, Inc.
- 11388 Sorrento Valley Road
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HALO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jan 2003|
|RV7||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2003|
|0J2O||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 2003|
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company’s products are based on the ENHANZE drug delivery technol ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/22 05:52|
|End of Day Share Price||2020/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.